characterized by life threatening arrhythmias elicited by physical and emotional stress in young individuals. The recessive form of CPVT is associated with mutation in the cardiac calsequestrin gene (CASQ2). We engineered and characterized a homozygous CASQ2 R33Q/R33Q mouse model that closely mimics the clinical phenotype of CPVT patients.
C atecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetically transmitted disease characterized by stress-or emotion-induced life-threatening arrhythmias occurring in the structurally intact heart. In 2001, 1 we demonstrated that mutations in the cardiac ryanodine receptor cause the autosomal dominant form of CPVT and subsequently reported that approximately 50% of CPVT patients carry mutations in RyR2. 2 In 2001, Lahat et al 3 showed that mutations in the cardiac calsequestrin gene (CASQ2) are responsible for the rare autosomal recessive form of the disease that accounts for approximately 3% of CPVT. 4 The identification of the genes underlying CPVT has had implications that extend beyond those impacting clinical management of patients inasmuch as it stimulated fundamental research targeted to understand the links between intracellular calcium regulation and arrhythmogenesis. We recently developed 5 a knock-in mouse model carrying the R4496C RyR2 mutation identified in the first genotyped CPVT family and demonstrated that the RyR2 R4496C mice develop bidirectional and polymorphic VT similar to those observed in patients. In this model we also demonstrated 6 the occurrence of delayed after depolarizations (DADs) induced by adrenergic stimulation in isolated myocytes from the heart of heterozygous mice, suggesting that arrhythmias are elicited by triggered activity. Recently 2 mutants CASQ2 knock-in mice models were developed by Song et al 7 : the first strain carries the homozygous point mutation discovered by Lahat et al 3 in the first recessive CPVT family (D307H), and the second strain carries a homozygous deletion ⌬E9/⌬E9; in analogy with RyR2 mice, 5 both models develop bidirectional-polymorphic VTs on sympathetic activation. Interestingly, the finding of CASQ2 reduction and calreticulin increase in both strains led to the hypothesis that reduction in CASQ2 activates a compensatory increase in calreticulin. 7 Here we describe a novel knock-in mouse carrier of a CASQ2 point mutation at position 33 (R33Q); the characterization of the CASQ2 R33Q/R33Q mouse model provides information that shed new light on the complex pathogenesis of recessive CPVT.
Materials and Methods
Detailed methods for mouse generation, electrophysiological measurements, immunofluorescence, real-time PCR, microarray, protein and electron microscopy analysis are reported in the online supplement (available online at http://circres.ahajournals.org).
Generation of Knock-In of R33Q CASQ2 in Mouse Model
The knock-in strain was generated by homologous recombination of the targeting vector with 129Sv/J embryonic stem cells genome. A 450-bp DNA segment encompassing 5Ј UTR and exon 1 of the CASQ2 was used to screen RPCI-21 PAC mouse genomic library. Positive clones were sequenced to define the structure of an 8.5-Kb region encompassing promoter, exon 1, and part of intron 1 of mouse CASQ2. This region was cloned in 3 parts and assembled into the targeting vector pFlrt (supplemental Figure I) . The linearized targeting vector was electroporated into 129Sv/J embryonic stem cells. The clone selected with G418 and gancyclovir was injected into C57BL/6NCrL blastocyts and transferred to pseudopregnant CD-1 females. Genotype was determined by sequencing of DNA extracted from tail biopsy specimens (DNasy Tissue Kit, Qiagen).
In Vivo Phenotype
In vivo ECG recording was performed using intraperitoneal devices (Data Sciences International). Surgery was performed under general anesthesia (Avertin 0.025 mg/kg) using a heating pad to keep body temperature at 37°C. Arrhythmias were defined according to Cerrone et al, 5 transthoracic 2-dimensional, M-mode, and Doppler echocardiography (CASQ2 WT/WT nϭ6; CASQ2 R33Q/R33Q nϭ6) was performed under isoflurane anesthesia with a 15 MHz linear transducer (HP Sonos 5500).
Histology
Hearts of 8-week-old mice (CASQ2 WT/WT nϭ2; CASQ2 R33Q/WT nϭ2; CASQ2 R33Q/R33Q nϭ2) were excised, stored in 10% formalin, and serially sectioned. Presence of macroscopic alterations of the heart was assessed by gross inspection; the heart was weighed to determine the heart/body weight ratio. Sections were stained with hematoxylin-eosin and Masson stain and evaluated by light microscopy.
Immunocytochemistry
Isolated ventricular myocytes were processed using an established protocol (see online data supplements). Coverslips were incubated with polyclonal anti-CASQ2 (Affinity Bioreagents, PA1-913) and monoclonal anti-␣-actinin (Sigma A7811) antibodies. After washing, cells were incubated with secondary antibodies. Confocal microscopy was performed with a TCS-SP digital scanning confocal microscope (Leica).
Electron Microscopy
The hearts of CASQ2 WT/WT (nϭ2) and CASQ2 R33Q/R33Q mice (nϭ2) were fixed by retrograde aortic perfusion (3.5% glutaraldehyde, 0.1 mol/L Na-Cacodylate buffer, pH 7.2). Specimens were processed as described in the online data supplements. Sections were examined with a Philips 410 Microscope (Fei Co.), equipped with a Hamamatsu C4742-95 digital imaging system (Advanced Microscopy Techniques).
The width of the lumen of junctional sarcoplasmic reticulum (jSR) was measured in electron micrographs taken at 135 000ϫ magnification using Adobe Photoshop and a grid of perpendicular lines randomly drawn perpendicularly across the jSR.
The total SR volume was calculated by the well-established stereology point counting technique 8 in electron micrographs taken at 24 000ϫ magnification from cross-sections of papillary cardiomyocytes. Multiple pictures were taken for each myocyte (36 and 46 cells in CSQ2
WT/WT and CSQ2 R33Q/R33Q mice, respectively). The images were covered with an orthogonal arrays of dots at a spacing of 0.17 m. The ratio of the dots' number falling over the SR to the total number of dots covering the whole micrograph was used to calculate the percentage of volume occupied by SR.
Patch Clamp Experiments in Isolated Ventricular Myocytes
Isolated cardiac myocytes were isolated using an established enzymatic digestion protocol. 9 Transmembrane action potentials and currents were recorded in whole cell configuration as previously described 6 using a MultiClamp 700B amplifier (Axon Instruments). Only quiescent, Ca-tolerant, rod-shaped cells with resting potential ՅϪ80 mV were used. Myocytes were electrically stimulated with 3ms/1.5 to 2.5 nA depolarizing pulses. Data were corrected for liquid junction potential before analysis. Action potential duration (APD) was measured at 90% and 50% of repolarization (APD 90 and APD 50 ). Triggered activity was defined as an unstimulated action potential arising from a delayed afterdepolarization (DAD) or a early afterdepolarization (EAD). L-type calcium current (I Ca-L ) was recorded with 200 ms depolarizing pulses from a holding potential of Ϫ40 mV, with 10 mV steps from Ϫ40 mV to ϩ60 mV. Current/voltage (I/V) curves were obtained 10 mV voltage steps (Ϫ40 mV to ϩ60 mV) from a holding potential of Ϫ40 mV. Protocols to assess releasable SR Ca 2ϩ content by integration of the sodium-calcium exchange current (NCX), steady-state inactivation (SSI), and steady state activation (SSA) curves are reported in the online supplements.
Real-Time PCR
Total RNA from the hearts of 8-week-old CASQ2 R33Q/R33Q (nϭ5) and CASQ2
WT/WT mice (nϭ5) was extracted (RNA Easy, Qiagen) and retro-transcribed with random examers (ThermoScript RT-PCR system-Invitrogen). Real Time quantification of targets genes (CASQ2, Triadin, Junctin, RyR2, SERCA2, Phospholamban and Calreticulin-list of primers provided in online supplements) and housekeeping reference transcript (GAPDH) was performed with CYBR, using the ABI PRISM 7000 detection system (Applied Biosystems). Relative gene expression was quantified as follows (from User Bulletin #2 for the ABI PRISM 7000): fold changeϭ 2 Ϫ⌬(⌬Ct) where ⌬CtϭCt target ϪCt reference and ⌬(⌬Ct)ϭ⌬Ct sample Ϫ⌬Ct control Ct is the fractional cycle number at which the fluorescence passes the fixed threshold. Data were analyzed with the comparative threshold cycle (Ct) relative-quantification method. Variance in fold change was calculated from genes mRNAs values (target gene) compared with control mRNAs (WT counterpart) and reference gene.
Microarray Analysis
Experiments were performed on total RNA from hearts of 8-weekold CASQ2 R33Q/R33Q (nϭ5) and CASQ2 WT/WT mice (nϭ5). Labeled cRNA probes were generated from total RNA using the GeneChip IVT Labeling Kit (Affymetrix). The cRNA was fragmented, biotinylated, and hybridized to Mouse Genome 430 2.0 Array chips, containing 14 000 mouse genes. Quality control and boxplot of raw intensities indicated the absence of outliers. Probe level was converted to expression values using both the Robust Multi-array Average (RMA) procedure and the MAS5.0 algorithms. Differentially expressed genes were identified using SAM by computing single-gene statistics and repeated permutations to determine correlation of expression level with the analyzed phenotypes. Supervised analyses was carried out to identify expression signatures of CASQ2 R33Q/R33Q samples as compared to CASQ2 WT/WT .
Protein Analysis
Total homogenates and microsomal fractions were obtained using standard methods (online data supplements) from 8-week-old 
Trypsin Digestion
Recombinant CASQ2-WT and CASQ2-R33Q proteins, generated and purified as described, 10 were digested by trypsin (CASQ2:trypsinϭ50:1 w/w; Sigma-Aldrich) in 20 mmol/L MOPS pH 7.2, 500 mmol/L KCl at 25°C for 30 minutes. Soyben trypsin inhibitor (inhibitor:trypsinϭ1:1 w/w; SERVA) halted the reaction and digested samples were electrophoresed on 10 to 17.5% polyacrylamide gradient gels. Slab gels were stained with Coomassie brilliant blue. Densitometric analysis was performed as described above. 
Statistical Analysis
Statistical analysis was performed using SPSS v14 package. Oneway ANOVA with Bonferroni posthoc analysis or Student t test were used. Western blot data were analyzed by densitometric analysis which retuned arbitrary units of band intensities. Chi square test (Fisher exact test) was used to compare difference of incidence of DADs/triggered activity. Data are expressed as meanϮSD unless specified. Values of PϽ0.05 were considered statistically significant.
Results

Phenotype of CASQ2
R33Q/R33Q Mice (Figure 1 ). Duration of sustained VT ranged from 5 to 232 seconds.
Light Microscopy of Ventricular Tissue and CASQ2 Localization by Immunohistochemistry
Histological examination of cardiac specimens failed to demonstrate gross structural abnormalities (Figure 2A ). CASQ2-R33Q and ␣-actinin colocalized at the Z-line both in homozygous CASQ2 R33Q/R33Q and CASQ2 WT/WT mice, as judged by immunofluorescence confocal microscopy ( Figure 2B ). The reduced fluorescence intensity of CASQ2 R33Q/R33Q samples is consistent with the decreased amount of CASQ2-R33Q detected by Western blotting (see below).
Electron Microscopy
Electron microscopy of both CASQ2
WT/WT and CASQ2
R33Q/R33Q
hearts showed that the SR forms junctions with T-tubules (dyads) in proximity of the Z line, as expected ( Figure 3 ). The percentage of cell volume occupied by SR was identical: 2.9Ϯ0.9 for CSQ2 WT/WT and 2.9Ϯ1.0 for CSQ2 R33Q/R33Q mice (Pϭ0.4; see supplemental Table II ). The jSR cisternae of WT samples were narrow and flat ( Figure 3A through 3C ), whereas they were much wider (41Ϯ10 nm versus 26Ϯ4 nm; PϽ0.0001, see supplemental Table II ) and had a more variable size in R33Q samples ( Figure 3D through 3F) .
The jSR of CASQ2 WT/WT myocytes contained an electrondense chain-like line, referable to condensed CASQ2 molecules, that runs parallel to the SR membrane ( Figure 3A through 3C, single arrows). and is confined to those junctional areas bearing feet, ie, the cytoplasmic domains of RyR2 ( Figure 3A and 3D, multiple arrows) 11 . On the other hand, the chain-like line of condensed CASQ2 was missing in CASQ2 R33Q/R33Q myocytes, and the SR lumen was either empty or contains some electrondense material that is not clustered as in SR/T-tubule junctions of WT myocytes ( Figure 3D through 3F ).
Electrophysiological Characterization of Cardiac Myocytes
We compared the action potential duration (APD) of CASQ2 . CASQ2-R33Q reduction could be accounted for by increased proteolysis: in vitro trypsin digestion of WT-CASQ2 and R33Q- 
CASQ2 was performed to test this hypothesis (Figure 6B
)
CASQ2
R33Q/R33Q hearts ( Figure 6C ). mRNA levels for RyR2, triadin, junctin, calreticulin, SERCA, and phospholamban extracted from CASQ2 R33Q/R33Q mice (nϭ5) were identical to those observed in CASQ2
WT/WT mice (nϭ5), as judged by real-time PCR. Similarly, we failed to detect differences in mRNA levels in 14 000 well characterized mouse genes in CASQ2 R33Q/R33Q hearts (nϭ5) versus CASQ2 WT/WT (nϭ5), using gene expression profiling microarrays (data not shown).
Discussion
CPVT is an inherited arrhythmogenic disorder characterized by syncopal events and sudden cardiac death, elicited by 
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physical and emotional stress, that manifests in the pediatric age. 2 Mutations in the cardiac ryanodine receptor (RyR2) and in the calsequestrin (CASQ2) genes are responsible for the autosomal dominant and recessive variants of CPVT, respectively. We recently reported the characterization of a knock-in mouse model carrier of the RyR2 R4496C mutation identified in the Italian family that led to the discovery of the genetic basis of autosomal dominant CPVT. 1 Remarkably the knock-in mice have a phenotype that closely resembles clinical manifestations of CPVT patients. 5 The extensive phenotypic characterization of the model showed that delayed after-depolarization and triggered activity represent the pivotal arrhythmogenic mechanism of CPVT. 6, 12 In the present study, we report the characterization of a knock-in mouse homozygous carrier of the CASQ2 R33Q mutation that we identified in highly symptomatic CPVT patients 13 : the main objective of the present study is to derive information germane to the understanding of the pathophysiology of the autosomal recessive form of CPVT that remains controversial. 7, 14 
Morphological Abnormalities and Contractile Function
CPVT is classified as an inherited arrhythmogenic disorder that occurs in individuals with a structurally intact heart: so far, in fact, no functional or morphological cardiac abnormalities have been described in patients with autosomal recessive CPVT. The murine models of recessive CPVT present modest structural abnormalities: similarly to our CASQ2 R33Q/R33Q mice, the CASQ2 knock out mice present normal cardiac contractility. However, ultrastructural assessment of CASQ2 R33Q/R33Q mice showed that the total SR volume is unchanged, whereas the width of the jSR is doubled. It remains to be clarified whether such features might represent the initial stages of a cardiomiopathy or are mere adaptive phenomena. In addition, CASQ2-R33Q appears not be properly clustered and this might also be related to the inability of R33Q to form Ca-dependent polymers 15 at physiological intra-SR [Ca 2ϩ ].
In Vivo and In Vitro Electrophysiological Profile
In analogy with what observed in the RyR2 knock-in mouse model, 5, 6 the CASQ2 R33Q/R33Q mice develop polymorphic and WT/WT (*PϽ0.001. RyR2 indicates ryanodine receptor; SERCA2, sarcoplasmic reticulum Ca ATPase; CALR, calreticulin; CASQ2, cardiac calsequestrin; TDN, triadin; JCT, junctin; PLB, phospholamban; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
bidirectional VT remarkably similar to arrhythmias developed by patients. At variance with the animal model of autosomal dominant CPVT, 5 however, CASQ2 R33Q/R33Q mice develop sustained VTs on exposure to environmental stress, ie, in the absence of any pharmacological challenge. In analogy with RyR2 R4496C/WT mice, cardiac myocytes isolated from the heart of CASQ2 R33Q/R33Q mice develop DADs and triggered activity when paced at faster rates in the presence of adrenergic stimulation. Interestingly at slow heart rate (1Hz), R33Q myocytes develop EADs that were never observed in RyR2 R4496C/WT myocytes (N Liu. unpublished data). It has been suggested that the occurrence of EADs involves reactivation of the L-type calcium current in the setting of action potential prolongation 16 . Because we did not observe APD prolongation in CASQ2 R33Q/R33Q myocytes ( Table) , a reactivation of inward calcium current seems an unlikely mechanism for EADs. Interestingly, EADs elicited in R33Q myocytes showed a take off potential between Ϫ50 mV and Ϫ60 mV that corresponds to the potential associated with the peak amplitude of the transient inward current in mouse myocytes (data not shown). 6 We therefore speculate that, in analogy with what we previously observed 17 in canine myocytes exposed to adrenergic stimulation, EADs in R33Q cardiac myocytes may be generated by the transient inward current elicited by abnormal SR calcium leak. However, because EADs were observed only at low pacing rates, it is unclear whether they have any physiological role in triggering ventricular tachyarrhythmias during adrenergic activation in vivo.
SR Calcium Content and Calsequestrin Depletion
To further investigate the mechanisms leading to arrhythmias in isolated R33Q cardiac myocytes, we measured the integral of I NCX evoked by the application of caffeine 18, 19 and showed a substantial decrease as compared to what observed in WT cells. There is an apparent discrepancy between these data and those reported by Terentyev et al 13 showing that in rat isolated myocytes overexpressing CASQ2-R33Q on top of endogenous CASQ2-WT, I NCX is unchanged despite the reduction of SR free calcium. Terentyev et al 13 linked the observed decrease in free calcium to the impairment of CASQ2 to act as the intraluminal calcium sensor of the RyR2 macromolecular complex 20 and to the impairment of the physiological deactivation of the RyR2 at low intraluminal calcium levels. Furthermore, based on single channel analysis, 21 we have shown that R33Q failed to inactivate RyR2 as intra-SR [Ca 2ϩ ] decreased. Thus, despite the leaky RyR2, normal calcium transients were recorded because of the compensatory effect of the high calcium binding provided by overexpressed CASQ2-R33Q and endogenous CASQ2-WT.
Because CASQ2 levels are markedly reduced in CASQ2 R33Q/R33Q mice (Figure 6 ), the limitations of the model used by Terentyev et al, 13 ie, CASQ2-R33Q overexpression in the presence of endogenous CASQ2-WT, have now become clear. Therefore, based on the present data, we propose that 2 consequences prompted by the mutation concur to the pathogenesis of the homozygous CASQ2 R33Q/R33Q phenotype: (1) reduction of CASQ2 levels (likely attributable to post/translational regulation leading to increased protein degradation, see below) and (2) impairment of RyR2 deactivation, as shown by Terentyev et al 13 and Qin et al. 21 Despite a substantial reduction of CASQ2 seems to be central in recessive CPVT, it is still a matter of debate whether a threshold decrease of CASQ2 is required for eliciting the CPVT phenotype or whether even a minor loss of CASQ2 increases propensity to arrhythmias. At variance with data reported in the heterozygous knock out mouse model, 22 most human heterozygous individuals carriers of premature truncations of CASQ2 are asymptomatic. We reported that all 9 carriers of the G112ϩ5X mutation leading to a premature stop codon had no clinical signs of CPVT. Postma et al 23 reported that 1 of 3 carriers of the heterozygous R33X mutation had arrhythmias, yet the clinical description of this individual is insufficient to support a causal link between the heterozygous mutation and the arrhythmias. It is possible that compensatory mechanisms to haploinsufficency of CASQ2 are different in humans and mice, and human beings may have the ability to upregulate the expression of the wild-type allele thus attenuating the consequences of CASQ2 deficiency in the heterozygous state. In the presence of heterozygous missense mutations, the residual function of the 50% mutant CASQ2 may be adequate to prevent functional impairment, as seen in our CASQ2 R33Q/WT mice that do not display reduction of CASQ2 levels and in analogy to the asymptomatic parents of the R33Q-linked CPVT patient.
Mechanisms Leading to Reduced CASQ2 in Recessive CPVT and Compensatory Responses
Recently Song et al 7 showed that the CASQ2 reduction observed in CASQ2 D307H/D307H mice is not paralleled by a reduction of CASQ2 mRNA, yet they did not provide any explanation to account for the protein reduction. In the CASQ2 R33Q/R33Q model, we observed a CASQ2 reduction in the presence of normal levels of mRNA and reasoned that CASQ2-R33Q might be more susceptible to proteolysis: a trypsin digestion test supported the view that accelerated CASQ2 catabolism is likely to underlie the observed CASQ2 reduction. Exposure of new proteolytic sites nearby the N or C terminus of the CASQ2-R33Q protein might be taken as indication of misfolding and protein instability, as compared to CASQ2-WT. CASQ2-R33Q because of its higher conformational flexibility, as recently shown, 24 might undergo accelerated in vivo degradation via proteasome, thus reducing effective CASQ2 content within the SR lumen. The relationships linking missense mutation, protein instability, and activation of posttranslational regulatory mechanisms are currently under investigation. A complementary mechanism for CASQ2-R33Q reduction might be attributable to inappropriate CASQ2 polymerization leading to defective SR retention, as suggested by Cala and coworkers. 25 In the CASQ2 D307H/D307H and CASQ2 ⌬ ⌭9/⌬⌭9 models, Song et al 7 found an increase in calreticulin and RyR2, and thus considered this process as a compensatory response to reduced CASQ2. In our model, we failed to observe such an adaptive response, and thus we argue that the increase in calreticulin and RyR2 might be a mutation-specific finding and should not be regarded as the univocal response to CASQ2 decrease. In our model, we found, instead, a decrease in the levels of triadin and junctin, in the absence of mRNA reduction, as assessed by real-time PCR: interestingly, also the knock out CASQ2 model 14 showed a similar reduction of triadin and junctin, yet the mechanism underlining this response remains so far undefined.
To provide a comprehensive assessment of the heart adaptive response to CASQ2-R33Q, we performed microarray studies to define the gene expression profiling of the heart of CASQ2 R33Q/R33Q mice versus that of their CASQ2
WT/WT littermates. Unexpectedly, no changes in mRNA levels were identified in any of the 14 000 genes probed suggesting that the heart does not activate adaptive transcriptional responses to mutant R33Q CASQ2, at least by 8 weeks of age.
Conclusion
In light of the unexpected 13 finding of the central role of CASQ2 decrease in the R33Q knock in mouse model, we now propose that CASQ2 reduction is one of the common pathogenetic mechanisms of autosomal recessive CPVT, as supported by the evidence that the CASQ2 knock out mice is a CPVT phenocopy. 14 We also suggest that the different missense mutations present in CPVT patients may be characterized by additional and specific functional abnormalities of CASQ2 (such as, CASQ2 polymerization impairment, altered calcium affinity, altered interaction with RyR2) leading to variable compensatory responses (increase in RyR2, increase in calreticulin, decrease in triadin and junctin . . .). The distinguishing features of each mutation may exert an additive effect on the common background of CASQ2 reduction that is likely to modulate the clinical expressivity of the disease.
